Affymax Rises on Deal With Fresenius for Kidney Therapy

Affymax Inc. rose the most in seven months after the biotechnology company and partner Takeda Pharmaceutical Co. agreed to supply their anemia drug Omontys to Fresenius Medical Care AG for use in dialysis patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.